CDDO-Me shows synergy with doxorubicin and overcomes drug resistance in MDR osteosarcoma cell lines. A) CDDO-Me inhibits cell growth in KHOSR2 and U-2OSTR. Cells were seeded at a density of 8,000 cells per well in a 96-well plate for 24 hours. The cells were then treated with 0.6 μM doxorubicin, 0.1 μM CDDO-Me, 0.3 μM CDDO-Me or combination of different two drugs for additional 24 hours. The cells were analyzed by MTT assay as described in Materials and Methods (B and C). CDDO-Me together with doxorubicin overcome drug resistance in both MDR KHOSR2 and U-2OSTR cells.
Ryu et al. BMC Cancer 2010 10:187 doi:10.1186/1471-2407-10-187